23,726
Participants
Start Date
August 20, 2020
Primary Completion Date
August 31, 2024
Study Completion Date
August 31, 2024
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)
Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)
Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
Placebo
Pharmaceutical form: liquid. Route of administration: intramuscular administration.
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination
Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
Investigational Site Number : 8000002, Entebbe
Investigational Site Number : 8000005, Entebbe
Investigational Site Number : 8000001, Kampala
Investigational Site Number : 2880001, Navrongo
Investigational Site Number : 8000013, Kampala
Investigational Site Number : 8000014, Lira
Investigational Site Number : 3400001, Municipio Del Distrito Central
Rochester Clinical Research, Inc. Site Number : 8400023, Rochester
Investigational Site Number : 3400002, San Pedro Sula
Investigational Site Number : 5240001, Nepalgunj
Investigational Site Number : 8000007, Kampala
Coastal Carolina Research Center - N Charleston Site Number : 8400022, North Charleston
Synexus Clinical Research Anderson Site Number : 8400007, Anderson
Investigational Site Number : 4040006, Eldoret
Synexus Clinical Research US, Inc. - Atlanta Site Number : 8400005, Atlanta
Synexus Clinical Research US, Inc. - Orlando Site Number : 8400020, Orlando
Optimal Research, LLC Site Number : 8400002, Melbourne
AES St. Petersburg Site Number : 8400017, Pinellas Park
AES - DRS - Simon Williamson Clinic, PC - Birmingham Site Number : 8400004, Birmingham
Optimal Research Alabama Site Number : 8400019, Huntsville
Investigational Site Number : 4840005, León
Investigational Site Number : 4840004, Acapulco de Juárez
Investigational Site Number : 4040002, Kisumu
Investigational Site Number : 4040003, Kisumu
Synexus US Columbus Site Number : 8400011, Columbus
Investigational Site Number : 4840003, Guadalajara
Synexus Akron Site Number : 8400009, Akron
Investigational Site Number : 5240003, Kathmandu
Investigational Site Number : 5240002, Dhulikhel
Synexus Clinical Research US, Inc. - Cincinnati Site Number : 8400010, Cincinnati
Synexus Clinical Research Evansville Site Number : 8400008, Evansville
Investigational Site Number : 4040011, Butere
American Indian Clinical Trials Research Network Site Number : 8400025, Rapid City
Synexus Clinical Research Chicago Site Number : 8400012, Chicago
Investigational Site Number : 4840008, Cuernavaca
Investigational Site Number : 4840006, Temixco
Synexus St. Louis Site Number : 8400006, St Louis
Synexus Dallas Site Number : 8400014, Dallas
Investigational Site Number : 1700005, Santiago de Cali
Synexus Clinical Research US, Inc. - San Antonio Site Number : 8400015, San Antonio
AES Austin Site Number : 8400003, Austin
Synexus Clinical Research US, Inc. Site Number : 8400013, Centennial
AES Salt Lake City Site Number : 8400016, Murray
Synexus Clinical Research US, Inc. - Henderson Site Number : 8400018, Henderson
Peninsula Research Associates, Inc. Site Number : 8400021, Rolling Hills Estates
Investigational Site Number : 4840002, Veracruz
Investigational Site Number : 1700001, Bogotá
Investigational Site Number : 3560005, Kanpur
Investigational Site Number : 1700007, Girardot
Investigational Site Number : 3560001, Jaipur
Investigational Site Number : 3560010, Ajmer
Investigational Site Number : 3560002, Ambawadi
Investigational Site Number : 3560009, Nagpur
Investigational Site Number : 3560003, Punjagutta
Investigational Site Number : 3560007, Belagavi
Investigational Site Number : 3560006, Tamilnadu
Investigational Site Number : 1700015, Quindío
Investigational Site Number : 1700004, Floridablanca
Investigational Site Number : 3560011, Odisha
Investigational Site Number : 3560004, Patna
Investigational Site Number : 1700010, Aguazul
Investigational Site Number : 1700002, Barranquilla
Investigational Site Number : 1700008, Barranquilla
Investigational Site Number : 1700006, Chía
Investigational Site Number : 1700009, Meta
Investigational Site Number : 1700003, Soledad
Investigational Site Number : 2880002, Kintampo
Investigational Site Number : 2880003, Kumasi
Investigational Site Number : 3920005, Chiyoda-ku,
Investigational Site Number : 3920004, Haramachi,Shinjuku-ku
Investigational Site Number : 3920003, Kouenji minami,Suginami-ku
Investigational Site Number : 3920001, Kyobashi Chuo-ku
Investigational Site Number : 3920002, Ohta-ku
Investigational Site Number : 4040004, Kericho
Investigational Site Number : 4040012, Kisumu
Investigational Site Number : 4040008, Mombasa
Investigational Site Number : 4040001, Nairobi
Investigational Site Number : 4040007, Nairobi
Investigational Site Number : 4040009, Thika
Investigational Site Number : 4840009, Mexico City
Investigational Site Number : 8000003, Kampala
Investigational Site Number : 8000004, Kampala
Investigational Site Number : 8040002, Kiev
Investigational Site Number : 8040004, Kyiv
Investigational Site Number : 8040003, Kyiv
Investigational Site Number : 8040001, Kyiv
Sanofi Pasteur, a Sanofi Company
INDUSTRY